Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Gamma in Leukocyte Adhesion Deficiency Type I
NCT00001905Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 1999
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon gamma-1b in leukocyte adhesion deficiency type I (LAD-I), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety and Adverse Events at 4 months and White Blood Cell Count in Mouth Rinse Specimen at 4 months. Started Apr 1999; status: completed.
02
Drugs
interferon gamma-1b
03
Conditions
leukocyte adhesion deficiency type I (LAD-I)
Beyond the preview
Go deeper on NCT00001905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001905.